摘要
目的开展对国产和进口甲巯咪唑在临床治疗甲状腺功能亢进症患者的药物经济学研究,为临床用药决策提供依据。方法采用回顾性研究筛选甲状腺功能亢进症患者,建立马尔可夫(Markov)模型对接受国产和进口甲巯咪唑药物治疗的患者进行模拟,并参考相关随机对照试验研究成果以及中外公开发表的文献。以不同治疗方案的费用、质量调整生命年(QALYs)作为评价指标。结果 2年国产组和进口组甲巯咪唑的效果值QALYs均为1.24年,国产组成本为2680.86元,比进口组减少115.00元,成本-效果比为4516.50元/QALY。结论本研究首次尝试应用Markov模型评价国产和进口甲巯咪唑治疗甲状腺功能亢进症中的成本和效果。2年内国产和进口甲巯咪唑治疗方案疗效相当,无显著差异,但国产甲巯咪唑组的成本更低,为治疗优势方案,更具有成本-效果性。
Objective To develop cost-effectiveness analysis for domestic and imported Methimazole in hyperthyroidism patients, in order to provide evidence-based reference for the clinical therapeutic regimen. Methods Patients with hyperthyroidism were analyzed retrospectively. Markov model was constructed to simulate development of healthy status of hyperthyroidism patients with domestic and imported Methimazole treatment. Randomized controlled trials（RCT） results and literature published at home and abroad were selected for reference. The costs and QALYs were considered as the estimated index in the two treatment protocols. Results 2-year cycle results showed that patients in domestic and imported Methimazole group were all 1.24 QALYs respectively. Cost of patients receiving domestic Methimazole was2680.86 yuan, which was 115.00 yuan less than that of import, and cost-effectiveness value was 4510.56 yuan/QALY.Conclusion It is the first time to establish the Markov model to evaluate the domestic and imported Methimazole in hyperthyroidism patients. There is no significant difference in curative effects between domestic and imported groups in 2years. However, the cost of domestic Methimazole is lower than that of imported Methimazole. It＇s the advantage treatment protocols, has better cost-effectiveness.
出处
《中国医药导报》
CAS
2016年第9期160-164,共5页
China Medical Herald
基金
河北省廊坊市科技支撑计划项目(2014013019)
